false
0001553643
0001553643
2026-11-16
2026-11-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): November
16, 2026
RELMADA THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
| Nevada |
|
001-39082 |
|
45-5401931 |
(State
or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer
Identification No.) |
2222 Ponce de Leon Blvd., Floor 3
Coral Gables,
FL |
|
33134 |
| (Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (786)
629 1376
| |
| (Former
name or former address, if changed since last report) |
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading Symbol |
|
Name
of each exchange on which registered |
| Common stock, $0.001 par value per share |
|
RLMD |
|
The
Nasdaq Capital
Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
7.01 Regulation FD Disclosure.
On
November 16, 2026 Relmada Therapeutics, Inc. (the “Company”), issued a press release announcing the appointment of Jørn
Skibsted Jakobsen, MD, PhD, as the Company’s Chief Development Officer. Pursuant to Regulation FD, the press release is furnished
with this Current Report as Exhibit 99.1.
The
information set forth in Item 7.01 of this Current Report on Form 8-K and in the attached Exhibit 99.1 is deemed to be “furnished”
and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), or otherwise subject to the liabilities of that Section. The information set forth in Item 7.01 of this
Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed incorporated by reference into any filing under the Exchange
Act or the Securities Act of 1933, as amended (the “Securities Act”), regardless of any general incorporation language in
such filing.
Item 9.01 Financial
Statements and Exhibits.
(d)
Exhibits.
| Exhibit No. |
|
Description |
| 99.1* |
|
Press
release issued on November 16, 2026 |
| 104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document) |
| * |
This
Exhibit attached to this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise
subject to liability under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act
or the Exchange Act, except as expressly set forth by specific reference in such filing. |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| Dated:
November 16, 2026 |
RELMADA
THERAPEUTICS, INC. |
| |
|
|
| |
By: |
/s/
Sergio Traversa |
| |
Name: |
Sergio
Traversa |
| |
Title: |
Chief
Executive Officer |
Exhibit 99.1
Relmada
Therapeutics Appoints Uro-Oncology Leader Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer
Former
ADSTILADRIN® global clinical development leader brings extensive uro-oncology expertise as Relmada prepares to initiate the Phase
3 SPECTRUM program for NDV-01
CORAL
GABLES, Fla., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”),
a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced
the appointment of Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer, Urology & Uro-Oncology. Dr. Jakobsen will
lead clinical development across Relmada’s pipeline, including the planned Phase 3 SPECTRUM registrational program for NDV-01.
Dr.
Jakobsen is an accomplished clinical development executive and board-certified urologist who served as the Head of Global Clinical Development
for the pivotal program of Ferring Pharmaceuticals’ ADSTILADRIN® that culminated in approvals from the U.S. Food and Drug Administration
(FDA), European Medicines Agency (EMA), Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), and Health Canada for the treatment
of non-muscle invasive bladder cancer (NMIBC). During his nine-year tenure at Ferring Pharmaceuticals, he led the company’s urology
and uro-oncology therapeutic area, overseeing global clinical development strategy, registrational studies, and regulatory interactions.
He also directed the lifecycle expansion of ADSTILADRIN’s clinical program into additional patient populations.
“I
am delighted to welcome Jørn to Relmada as we enter a critical phase in the development of NDV-01,” said Sergio Traversa,
Chief Executive Officer of Relmada Therapeutics. “Jørn has treated patients with bladder cancer and led the pivotal
development program for ADSTILADRIN, the first intravesical gene therapy approved globally by the FDA, EMA, PMDA, and Health Canada for
the treatment of NMIBC. His experience navigating global regulatory authorities and guiding clinical strategy will be invaluable as we
prepare to initiate the SPECTRUM registrational Phase 3 program. We are building a development organization with the leadership required
to realize the full potential of NDV-01, and I am thrilled to have Jørn helping lead that effort.”
“I
am excited to join Relmada because I believe NDV-01 has the potential to transform how we treat patients with NMIBC,” said Jørn
Skibsted Jakobsen, MD, PhD, Chief Development Officer, Urology & Uro-Oncology, of Relmada Therapeutics. “The Phase 2 results
for NDV-01 are compelling, demonstrating high, durable complete response rates alongside favorable safety and tolerability. Equally important
is the potential to offer a therapy that fits seamlessly into everyday urology practice through convenient in-office administration with
a ready-to-use product. I look forward to collaborating with the Relmada team to advance NDV-01 through the SPECTRUM program and bring
this important new treatment option to patients with NMIBC.”
About
Jørn Skibsted Jakobsen, MD, PhD
Jørn
Skibsted Jakobsen, MD, PhD, is a physician-scientist, board-certified urologist, and biopharmaceutical development executive with more
than 25 years of experience in urologic oncology practice, clinical research, and drug development.
Most
recently, Dr. Jakobsen served as Vice President, Therapeutic Area Head, Urology & Uro-Oncology, at Ferring Pharmaceuticals. During
his tenure, he led the pivotal ADSTILADRIN program that culminated in FDA and global approvals and oversaw its subsequent clinical development
and evidence generation, including studies supporting potential label expansion. He also led global clinical strategy and regulatory
interactions and chaired the Scientific Advisory Committee of Ferring Ventures.
Before
joining Ferring, Dr. Jakobsen served as Chief Urologist at Herlev University Hospital in Denmark, where he treated patients with bladder
and prostate cancer. He previously served as a consultant urologist at Odense University Hospital. His professional service includes
the Scandinavian Prostate Cancer Group and the Committee for Experimental Surgery in Oncology under The Danish Health Authority.
Dr.
Jakobsen holds an MD from the University of Southern Denmark, a PhD from its Faculty of Health Sciences, and a Diploma in Pharmaceutical
Medicine from the European Center of Pharmaceutical Medicine at the University of Basel.
Third-party
products mentioned herein are the trademarks of their respective owners.
About
Relmada Therapeutics, Inc.
Relmada
Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous
system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through clinical development with the potential to address
significant unmet needs.
For
more information, visit www.relmada.com.
Forward-Looking
Statements:
The
Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This
press release contains statements which constitute “forward-looking statements” within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statement that is not historical in nature is a forward-looking
statement and may be identified by the use of words and phrases such as “if”, “may”, “expects”, “anticipates”,
“believes”, “will”, “will likely result”, “will continue”, “plans to”, “potential”,
“promising”, and similar expressions. These statements are based on management’s current expectations and beliefs and
are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described
in the forward-looking statements, including potential for Relmada’s product candidates to fail to progress, potential delays in
or failure to initiate the planned Phase 3 SPECTRUM program for NDV-01, the Company’s ability to attract and retain key personnel,
including Dr. Jakobsen, and to successfully integrate new members of its leadership team, potential for Phase 2 NDV-01 data to fail to
continue to deliver positive results supporting further development, potential for clinical trials to fail to deliver statistically and/or
clinically significant evidence of efficacy and/or safety, failure of interim or top-line results to accurately reflect the complete
results of the trial, failure of planned or ongoing preclinical and clinical studies to demonstrate expected results, potential failure
to obtain or continue to secure FDA agreement on the regulatory path for NDV-01 and/or sepranolone, or that future NDV-01 and/or sepranolone
clinical results will be acceptable to the FDA, failure to successfully execute manufacturing and CMC activities for NDV-01 and/or sepranolone,
including GMP manufacture of clinical trial material, manufacturing scale-up, process validation, timing of completion of manufacturing
activities, and regulatory acceptance of manufacturing-related submissions, failure to secure adequate NDV-01 and/or sepranolone drug
supply, failure of pending patent applications to result in issued patents, or issued patents being challenged and invalidated by third
parties or not providing us with any competitive advantages, the Company’s cash runway and sufficiency of the Company’s cash
resources and uncertainties inherent in estimating the Company’s cash runway, future expenses and other financial results, including
its ability to fund future operations, including clinical trials, and the other risk factors described under the heading “Risk
Factors” set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, its subsequent Quarterly
Reports on Form 10-Q and other reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual
results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement,
whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify
all the risks, uncertainties and other factors that may affect future results and that the risks described herein are not a complete
list.
Investor
Contact:
Brian
Ritchie
LifeSci
Advisors
britchie@lifesciadvisors.com
Media
Inquiries:
Corporate
Communications
media@relmada.com